To explore the associations of CD8+ T cells in the peripheral blood with the responses to ICI therapy in patients with advanced gastric cancer, some CD8+ T cell subsets before receiving sintilimab plus oxaliplatin and capecitabine therapy were firstly determined and compared between R and NonR gastric cancer patients. Here, CD8A is linked to gastric cancer.